On October 9, Lvzhu Biotech (02480) announced the successful completion of its Phase I clinical trial of LZ901 in the United States. The trial, which began in February 2023 and enrolled 66 healthy subjects aged 50 to 70, showed good safety and immunogenicity in both high- and low-dose groups of the LZ901 vaccine.
　　During the trial, only mild vaccine-related adverse reactions were reported in the low-dose group, with an incidence of 4.35%. Neither the high-dose group nor the placebo group experienced any such adverse reactions. LZ901 is a recombinant herpes zoster vaccine independently developed by the company, designed to prevent herpes zoster and its related complications in adults aged 40 and older. The vaccine's Phase III clinical trial in China has achieved pre-specified objectives and anticipated results.
　　Currently, LZ901 biological productsThe license application has been accepted by the China National Medical Products Administration and is currently under evaluation. The Company reminds shareholders and investors that there can be no guarantee that LZ901 will ultimately be successfully developed and marketed, and advises caution when buying or selling shares.

https://finance.eastmoney.com/a/202510093529637045.html